Literature DB >> 23748711

Acute phase response after zoledronic acid is associated with long-term effects on white blood cells.

Maurizio Rossini1, Silvano Adami, Ombretta Viapiana, Gaia Tripi, Roberta Zanotti, Riccardo Ortolani, Antonio Vella, Sonila Troplini, Davide Gatti.   

Abstract

We have recently reported a long-lasting decrease in circulating γδ T cells in osteoporotic patients on oral amino-bisphosphonates (N-BPs). Here we verify whether these changes are associated with the occurrence of acute phase response (APR) to intravenous (IV) zoledronic acid (ZOL) or changes of other circulating white blood cells (WBC). WBC count was obtained before and 1 year after a single IV administration of 5 mg ZOL in 36 osteoporotic patients (mean age 72 ± 9, range 45-86 years) without other relevant diseases; 12 of 36 patients developed the classical APR. After 1 year in the patients who experienced an APR, but not in the others, a significant decrease not only of γδ T cells (-30 %), but also of total lymphocytes (-11 %) and eosinophils (-27 %), was observed. The mechanism leading to the observed decrease of circulating lymphocytes and eosinophils remains unclear, but our observation opens a new frontier for the understanding of the immunoeffects of N-BPs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23748711     DOI: 10.1007/s00223-013-9750-6

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  9 in total

1.  Effects of denosumab on peripheral lymphocyte subpopulations.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Francesco Ghellere; Gaia Tripi; Riccardo Ortolani; Roberta Zanotti; Davide Gatti
Journal:  Endocrine       Date:  2015-08-20       Impact factor: 3.633

Review 2.  Management of patients with complex regional pain syndrome type I.

Authors:  D Gatti; M Rossini; S Adami
Journal:  Osteoporos Int       Date:  2016-02-29       Impact factor: 4.507

3.  Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.

Authors:  A Kyrgidis; M P Yavropoulou; R Lagoudaki; C Andreadis; K Antoniades; D Kouvelas
Journal:  Osteoporos Int       Date:  2016-11-17       Impact factor: 4.507

4.  Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.

Authors:  E O Billington; A Horne; G D Gamble; K Maslowski; M House; I R Reid
Journal:  Osteoporos Int       Date:  2017-02-23       Impact factor: 4.507

5.  The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes.

Authors:  Luca Degli Esposti; Valentina Perrone; Diego Sangiorgi; Margherita Andretta; Fausto Bartolini; Arturo Cavaliere; Andrea Ciaccia; Stefania Dell'orco; Stefano Grego; Sara Salzano; Loredana Ubertazzo; Adriano Vercellone; Davide Gatti; Angelo Fassio; Ombretta Viapiana; Maurizio Rossini; Giovanni Adami
Journal:  J Bone Miner Res       Date:  2021-08-22       Impact factor: 6.390

6.  Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial.

Authors:  Maurizio Rossini; Silvano Adami; Elena Fracassi; Ombretta Viapiana; Giovanni Orsolini; Maria Rosaria Povino; Luca Idolazzi; Davide Gatti
Journal:  Rheumatol Int       Date:  2014-08-01       Impact factor: 2.631

Review 7.  Focal bone involvement in inflammatory arthritis: the role of IL17.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Elena Fracassi; Davide Gatti
Journal:  Rheumatol Int       Date:  2015-10-31       Impact factor: 2.631

8.  Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid Ophthalmopathy.

Authors:  James Yu; Jian Guan
Journal:  Cureus       Date:  2020-12-11

9.  Investigation of Intravenous Zoledronic Acid Therapy on Circulating Lymphocyte Subpopulation in Patients with Primary Osteoporosis: A Pilot Study.

Authors:  Min Cui; Na Zhang; Gang Zhang; Lei Han; Ling Zhi Yu
Journal:  Curr Ther Res Clin Exp       Date:  2021-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.